Matthew Biancalana Selected Research

Neoadjuvant Therapy

10/2023

Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew Biancalana Research Topics

Disease

4	Neoplasms (Cancer) 10/2023 - 01/2018
2	Breast Neoplasms (Breast Cancer) 10/2023 - 01/2023
2	Triple Negative Breast Neoplasms 10/2023 - 01/2023
2	Proteostasis Deficiencies 02/2010 - 01/2009
1	Pathologic Complete Response 01/2023
1	Lymphadenopathy 01/2020
1	Cytopenia 01/2020
1	Dysgammaglobulinemia 01/2020
1	Liver Diseases (Liver Disease) 01/2020
1	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 01/2020
1	Idiopathic CD4-Positive T-Lymphocytopenia (T Lymphocytopenia, Idiopathic CD4 Positive) 01/2020
1	Epstein-Barr Virus Infections 01/2020
1	Autoimmune Lymphoproliferative Syndrome 01/2020
1	Pathologic Constriction (Stenosis) 06/2017
1	Disease Progression 01/2014

Drug/Important Bio-Agent (IBA)

2	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2020
1	human ERBB2 proteinIBA 10/2023
1	Hormones (Hormone)IBA 10/2023
1	N-acetyltalosaminuronic acid (NAT)IBA 10/2023
1	AntibodiesIBA 01/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	Immune Checkpoint InhibitorsIBA 01/2023
1	MagnesiumIBA 01/2020
1	Glycoproteins (Glycoprotein)IBA 01/2020
1	NK Cell Lectin-Like Receptor Subfamily KIBA 01/2020
1	Phenobarbital (Luminal)FDA Link 06/2017
1	Sirolimus (Rapamycin)FDA Link 01/2014
1	Amyloid (Amyloid Fibrils)IBA 02/2010
1	Coloring Agents (Dyes)IBA 01/2009
1	thioflavin TIBA 01/2009

Therapy/Procedure

2	Therapeutics 10/2023 - 01/2023
2	Immunotherapy 01/2023 - 01/2018
1	Neoadjuvant Therapy 10/2023
1	Precision Medicine 10/2023